Saw this post at Practice Update site - more reason for newly diagnosed patients (like myself) to stay the course:
"Patient-Reported Outcomes Following Abiraterone Acetate Plus Prednisone Added to ADT for Newly Diagnosed Metastatic Castration-Naïve Prostate Cancer"
This analysis of the LATITUDE trial was designed to evaluate patient-reported outcomes with ADT plus abiraterone/prednisone or placebo in men with castration-naïve prostate cancer. In LATITUDE, 1199 patients were randomized to ADT plus abiraterone/prednisone (597) or to ADT plus placebo (602). Median follow-up in the ADT plus abiraterone/prednisone group was 30.9 months; in the ADT plus placebo group, it was 29.7 months. Neither arm reached the median time to worst pain intensity progression, nor median time to worst fatigue intensity. The median time to deterioration of functional status was 12.9 months in the ADT plus abiraterone/prednisone group and 8.3 months in the ADT plus placebo group.
Patients in the abiraterone/prednisone arm reported improvements in pain, prostate cancer symptoms, fatigue, functional decline, and overall health-related quality of life compared with patients in the placebo arm.
– Neil Majithia, MD"
and the link: